CNBC’s Jim Cramer delivers his daily Mad Dash.

July 7 (Reuters) - Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering ...

"Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...

Like tectonic plates colliding, humanism and the humanities are confronting movements that question long-held definitions of ...

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its ...

In a world where billions of people are connected through social media, are we truly becoming more connected, or are we the ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Health insurers are increasingly embracing artificial intelligence as part of their business models, bullish on the ...

Veteran biosensor innovator and technology leader brings decades of experience developing and scaling breakthrough ...